See more : Armata Pharmaceuticals, Inc. (ARMP) Income Statement Analysis – Financial Results
Complete financial analysis of Mountain Crest Acquisition Corp. II (MCAD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mountain Crest Acquisition Corp. II, a leading company in the Shell Companies industry within the Financial Services sector.
You may be interested
- Florida Canyon Gold Inc. (FCGV.V) Income Statement Analysis – Financial Results
- Amplifon S.p.A. (AMP.MI) Income Statement Analysis – Financial Results
- Kyobo Securities Co ., Ltd (030610.KS) Income Statement Analysis – Financial Results
- KFC, Ltd. (3420.T) Income Statement Analysis – Financial Results
- Hangzhou Huaxing Chuangye Communication Technology Co., Ltd. (300025.SZ) Income Statement Analysis – Financial Results
Mountain Crest Acquisition Corp. II (MCAD)
Industry: Shell Companies
Sector: Financial Services
About Mountain Crest Acquisition Corp. II
Mountain Crest Acquisition Corp. II, a blank check company, intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or related business combination with one or more businesses. The company was founded in 2020 and is based in New York, New York.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 8.00K | 18.00K |
| Cost of Revenue | 2.73M | 1.62M | 682.00K | 898.00K |
| Gross Profit | -2.73M | -1.62M | -674.00K | -880.00K |
| Gross Profit Ratio | 0.00% | 0.00% | -8,425.00% | -4,888.89% |
| Research & Development | 16.44M | 19.44M | 2.98M | 2.29M |
| General & Administrative | 14.84M | 8.79M | 2.46M | 2.20M |
| Selling & Marketing | 6.98M | 2.34M | 216.00K | 406.00K |
| SG&A | 21.82M | 11.12M | 2.67M | 2.60M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 38.26M | 30.56M | 5.65M | 4.89M |
| Cost & Expenses | 38.26M | 30.56M | 6.33M | 5.79M |
| Interest Income | 1.49K | 185.00 | 100.00 | 11.00 |
| Interest Expense | 1.49M | 185.00K | 100.00K | 11.00K |
| Depreciation & Amortization | 2.73M | 1.62M | 75.00K | 72.00K |
| EBITDA | -38.26M | -30.56M | -6.25M | -5.70M |
| EBITDA Ratio | 0.00% | 0.00% | -78,100.00% | -31,672.22% |
| Operating Income | -38.26M | -30.56M | -6.32M | -5.77M |
| Operating Income Ratio | 0.00% | 0.00% | -79,037.50% | -32,072.22% |
| Total Other Income/Expenses | -1.49M | -9.93M | 89.00K | -11.00K |
| Income Before Tax | -39.75M | -40.49M | -6.23M | -5.78M |
| Income Before Tax Ratio | 0.00% | 0.00% | -77,925.00% | -32,133.33% |
| Income Tax Expense | 7.00K | -153.00K | 153.00K | 11.00K |
| Net Income | -39.76M | -40.34M | -6.39M | -5.80M |
| Net Income Ratio | 0.00% | 0.00% | -79,837.50% | -32,194.44% |
| EPS | -1.69 | -1.71 | -0.85 | -0.25 |
| EPS Diluted | -1.69 | -1.71 | -0.85 | -0.25 |
| Weighted Avg Shares Out | 23.56M | 23.60M | 7.56M | 23.60M |
| Weighted Avg Shares Out (Dil) | 23.56M | 23.60M | 7.56M | 23.60M |
Mountain Crest Acquisition Corp. II and Better Therapeutics, Inc. Announce Registration Statement Effectiveness and Scheduled Special Meeting to Approve Business Combination on October 27, 2021
NEW YORK and SAN FRANCISCO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. II (NASDAQ: MCAD, “Mountain Crest II”), a publicly-traded special purpose acquisition company and Better Therapeutics, Inc. (“Better Therapeutics”), a prescription digital therapeutics (PDT) company developing...
Better Therapeutics to Participate in Lake Street's 5th Annual Best Ideas Growth (BIG5) Conference on September 14-15, 2021
SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (“Better Therapeutics”), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, has been invited to present at the Lake Street's 5th Annual Best Ideas Growth (BIG5) Conference,...
Better Therapeutics Expands Real-World Evidence Study Initiative With Addition of Catalyst Health Network
SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (“Better Therapeutics”), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, in partnership with Catalyst Health Network (“Catalyst”), today announced the commencement of a real-world evidence study...
Better Therapeutics and Colorado Prevention Center Clinical Research Launch Real-World Evidence Study of Prescription Digital Therapeutic for Type 2 Diabetes
SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (“Better Therapeutics”), a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, in partnership with Colorado Prevention Center (CPC) Clinical Research, affiliated with the University of Colorado Anschutz...
Better Therapeutics Launches Real World Evidence Study of Prescription Digital Therapeutic for Type 2 Diabetes
SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (“Better Therapeutics”), a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the commencement of a real-world evidence study with Steward Health Care to evaluate the...
Source: https://incomestatements.info
Category: Stock Reports